SCHEMBL2506958

SCHEMBL2506958

O=C(Nc1cc(Br)cnc1Cl)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 2/20 0.52
ATM Q13315 1/20 0.52
PKM P14618 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
GAA P10253 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
TUBB4A P04350 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220700 0.86 KDM4E (0.63) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL2481316 0.82 LMNA (0.60) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL6537919 0.81 CYP1A2 (0.55) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL2509493 0.80 NPC1 (0.54) SMN1; SMN2KDM4EALDH1A1HPGDRAB9A
SCHEMBL986256 0.80 HTT (0.65) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL17047612 0.78 MEN1 (0.57) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL890832 0.78 KDM4E (0.73) MEN1KMT2ASMN1; SMN2HTTPKM
SCHEMBL17803114 0.75 HTT (0.53) SMN1; SMN2HTTATMPKML3MBTL1
SCHEMBL16973835 0.75 CYP1A2 (0.59) MEN1KMT2ASMN1; SMN2HTTATM
SCHEMBL6107391 0.75 CYP1A2 (0.58) MEN1KMT2ASMN1; SMN2HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541407-B2 Substituted benzo-pyrido-triazolo-diazepine compounds ARQULE, INC. (US) 2013-09-24 US disclosed
US-8541407-B2 Substituted benzo-pyrido-triazolo-diazepine compounds ARQULE, INC. (US) 2013-09-24 US disclosed
WO-2011123678-A2 SUBSTITUTED BENZO-PYRIDO-TRIAZOLO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2011-10-06 WO disclosed
WO-2011123678-A2 SUBSTITUTED BENZO-PYRIDO-TRIAZOLO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2011-10-06 WO disclosed
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds ARQULE, INC. (US) 2011-10-06 US disclosed
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds ARQULE, INC. (US) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds BRD4, PDXK, THPO MEN1 555/4885KMT2A 1644/4885SMN1; SMN2 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.